RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
  Avian Influenza
  Cholera
  Hemorrhagic Fevers
   Marburg
  Poliomyelitis
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Marburg Channel

subscribe to Marburg newsletter
Medical News : Epidemics : Hemorrhagic Fevers : Marburg

   EMAIL   |   PRINT
Web-based Clinical Trial Against Marburg Virus Epidemic in Angola

Apr 29, 2005 - 8:08:00 PM
"Our positive experience so far with West Nile virus encephalitis gives us hope that our approach will be successful against other lethal viruses like Marburg virus. We're grateful to Angola for allowing us to try to help during the current awful epidemic."

 
[RxPG] GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that it has launched a free clinical trial to combat the current Marburg virus epidemic in Angola.

Marburg virus causes a hemorrhagic fever which is fatal in 80% of cases. The current epidemic, the largest in history, began in the northern province of Uige in Angola in early March. It has since spread throughout much of Angola. So far, over 240 people have died, many of them children, and another 264 people are currently infected.

Marburg virus is considered a prime candidate for use by viral bioterrorists.

GenoMed believes it has a broad-spectrum viral antidote, which it has been testing successfully against West Nile virus for the past two summers. It should work equally well against influenza, avian influenza, SARS, respiratory syncytial virus (RSV) in children, and the common cold. It may also be effective against HIV and tuberculosis (Tb). Tb, of course, is caused by the tubercle bacillus, a kind of bacteria.

Said Dr. David Moskowitz, Chief Medical & Executive Officer for GenoMed, "Our positive experience so far with West Nile virus encephalitis gives us hope that our approach will be successful against other lethal viruses like Marburg virus. We're grateful to Angola for allowing us to try to help during the current awful epidemic."

Dr. Moskowitz went on to say, "The Internet now makes it possible for anybody to enroll in our free clinical trial at any time of day or night anywhere in the world, simply by going to our website and clicking on the link for the trial. People will have to enter their email address so that we can follow up with them and eventually publish our results. In return for their email address, they'll be able to download the documents they'll need to show their physician in order to get started immediately on our trial. A family member could easily do this for a child who is sick. The drugs we use are available in every drug store around the world."



Publication: GenoMed, Inc.
On the web: www.genomed.com 

Advertise in this space for $10 per month. Contact us today.


Related Marburg News
New Marburg Cases Identified in Uige
Web-based Clinical Trial Against Marburg Virus Epidemic in Angola
Assessment of the Marburg haemorrhagic fever Outbreak
215 Dead from Marburg haemorrhagic fever
210 dead from Marburg haemorrhagic fever in Angola
Launch of a flash funding appeal for Marburg Outbreak
Uige Province remains the Epicentre of Marburg
Marburg haemorrhagic fever in Angola

Subscribe to Marburg Newsletter

Enter your email address:


 Additional information about the news article
About GenoMed

GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. In autoimmune diseases, a person's own immune system causes the disease. Like most viruses, Marburg virus appears to hurt patients by overstimulating the immune system, and cannot cause damage by itself.

For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-983-9933, email: [email protected], or visit GenoMed at www.genomed.com.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether GenoMed's approach will lower mortality from Marburg virus; (b) whether GenoMed's server will hold up to international demand; (c) whether we will have sufficient financing to conduct our research and development; and (d) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)